132 related articles for article (PubMed ID: 38000932)
1. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
Abel EJ; Master VA; Spiess PE; Raman JD; Shapiro DD; Sexton WJ; Zemp L; Patil D; Lauer K; Allen GO; Matin SF; Karam JA
Eur Urol Oncol; 2024 Apr; 7(2):302-303. PubMed ID: 38000932
[No Abstract] [Full Text] [Related]
2. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
[No Abstract] [Full Text] [Related]
3. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
[No Abstract] [Full Text] [Related]
4. Reply to Kunlin Yang, Xuesong Li, and Liqun Zhou's Letter to the Editor re: Eduard Roussel, Giovanni Tasso, Riccardo Campi, et al. Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration. Eur Urol 2021;79:133-40.
Roussel E; Tasso G; Albersen M
Eur Urol; 2021 Jul; 80(1):e32. PubMed ID: 33941401
[No Abstract] [Full Text] [Related]
5. Reply to Daniel D. Shapiro, Jose A. Karam, Viraj A. Master, et al.'s Letter to the Editor re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610.
Yip W; Ghoreifi A; Djaladat H
Eur Urol Oncol; 2023 Dec; 6(6):637. PubMed ID: 37316397
[No Abstract] [Full Text] [Related]
6. Reply to Zhenjie Wu and Linhui Wang's Letter to the Editor re: Riccardo Bertolo, Riccardo Autorino, Giuseppe Simone, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). Eur Urol 2018;74:226-32.
Bertolo R; Autorino R
Eur Urol; 2018 Dec; 74(6):e147-e148. PubMed ID: 30193967
[No Abstract] [Full Text] [Related]
7. Reply to Lorenzo Marconi, Steven MacLennan, Thomas B.L. Lam, et al's Letter to the Editor re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606-17.
Derweesh IH; Mir MC; Autorino R
Eur Urol; 2017 Sep; 72(3):e61-e62. PubMed ID: 28642021
[No Abstract] [Full Text] [Related]
8. Reply to Takeshi Takahashi's Letter to the Editor re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol 2021;80;760-2. Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki: Re-envisioning the Value of Clinical Research to Foster the Progress of Evidence-based Urology: The Case of Partial Nephrectomy for cT2 Renal Masses.
Campi R; Bertolo R; Minervini A;
Eur Urol; 2022 Feb; 81(2):e46-e47. PubMed ID: 34887115
[No Abstract] [Full Text] [Related]
9. Re: Eduard Roussel, Giovanni Tasso, Riccardo Campi, et al. Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration. Eur Urol 2021;79:133-40.
Yang K; Li X; Zhou L
Eur Urol; 2021 Jul; 80(1):e30-e31. PubMed ID: 33941400
[No Abstract] [Full Text] [Related]
10. Reply to Pranav Sharma, Asad Sawar and Philippe Spiess' letter to the editor re: re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8.
Rogers CG; Barod R; Schwartz S; Menon M
Eur Urol; 2015 Oct; 68(4):e81. PubMed ID: 26004799
[No Abstract] [Full Text] [Related]
11. Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73.
Marconi L; Lam TB; Bex A; Ljungberg B; Volpe A
Eur Urol; 2016 Jun; 69(6):e119-20. PubMed ID: 26776936
[No Abstract] [Full Text] [Related]
12. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
Shapiro DD; Karam JA; Master VA; Zemp LW; Sexton WJ; Matin SF; Spiess PE; Jason Abel E
Eur Urol; 2023 Aug; 84(2):e55-e56. PubMed ID: 37149462
[No Abstract] [Full Text] [Related]
13. Re: Riccardo Bertolo, Riccardo Autorino, Giuseppe Simone, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). Eur Urol 2018;74:226-32.
Wu Z; Wang L
Eur Urol; 2018 Dec; 74(6):e145-e146. PubMed ID: 30193968
[No Abstract] [Full Text] [Related]
14. Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V-Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007.
Zilli T; Ost P
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38418267
[No Abstract] [Full Text] [Related]
15. Re: Kosuke Takemura, Matthew S. Ernst, Vishal Navani, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.002.
Ishiyama Y; Urabe F
Eur Urol Oncol; 2024 Jun; 7(3):642-643. PubMed ID: 38238222
[No Abstract] [Full Text] [Related]
16. Re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol. 2021;80:760-2: Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki.
Takahashi T
Eur Urol; 2022 Feb; 81(2):e44-e45. PubMed ID: 34887116
[No Abstract] [Full Text] [Related]
17. Re: Pawel Rajwa, Daniele Robesti, Michael Chaloupka, et al. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.006.
Onal C; Elmali A; Cem Guler O
Eur Urol Oncol; 2024 Jun; 7(3):644-645. PubMed ID: 38365504
[No Abstract] [Full Text] [Related]
18. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
Mollica V; Rizzo A; Massari F
Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
[No Abstract] [Full Text] [Related]
19. Reply to Chen Cai, Huamao Ye, and Bing Liu's letter to the editor re: Francesco Greco, Riccardo Autorino, Koon H. Rha, et al. Laparoendoscopic single-site partial nephrectomy: a multi-institutional outcome analysis. Eur Urol 2013;64:314-22.
Greco F; Autorino R
Eur Urol; 2013 Aug; 64(2):e33-4. PubMed ID: 23628494
[No Abstract] [Full Text] [Related]
20. Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019, 76:871.
Sighinolfi MC; Rocco B
Eur Urol; 2020 May; 77(5):e128-e129. PubMed ID: 32067794
[No Abstract] [Full Text] [Related]
[Next] [New Search]
